Physician profile
Michael E Ruff
NPI 1932184256
$2,044.62
in general payments reported to CMS, 2019-2025
22 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $124 · 2021: $187 · 2022: $348 · 2023: $357 · 2024: $493 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $442.09 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $312.10 | 2019-2024 | Dyanavel Xr |
| Alphatec Spine, INC | $244.61 | 2024 | Other - Miscellaneous |
| Corium, LLC | $173.97 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $134.67 | 2019-2023 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $106.14 | 2019-2023 | Gattex |
| Sanofi Pasteur INC. | $98.66 | 2020-2025 | |
| Collegium Pharmaceutical, INC. | $85.81 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $82.69 | 2020-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Seqirus USA INC | $61.58 | 2021-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Neurelis, INC. | $43.24 | 2021-2023 | Valtoco |
| Pfizer INC. | $40.06 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $39.08 | 2024 | |
| Shire North American Group INC | $38.41 | 2019 | |
| Supernus Pharmaceuticals, INC. | $27.83 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $22.21 | 2025 | Ycanth |
| Aquestive Therapeutics, INC. | $21.83 | 2025 | |
| Cranial Technologies, INC | $16.48 | 2023 | Doc Band |
| Vertical Pharmaceuticals, LLC | $14.42 | 2024 | Relexxii |
| Sobi, INC | $14.37 | 2019 | |
| Sarepta Therapeutics, INC. | $12.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.